Wallace D J, Metzger A L, Stecher V J, Turnbull B A, Kern P A
Department of Medicine, Cedars-Sinai Medical Center/UCLA School of Medicine.
Am J Med. 1990 Sep;89(3):322-6. doi: 10.1016/0002-9343(90)90345-e.
The effects of hydroxychloroquine (HCQ) on serum levels of cholesterol, triglycerides, and high- (HDL) and low-density lipoprotein (LDL) were studied in patients with rheumatoid arthritis or systemic lupus erythematosus.
A total of 155 women were divided into the following treatment groups: Group A: patients taking HCQ and no steroids (n = 58); Group B: patients taking steroids and no HCQ (n = 35); Group C: patients receiving both HCQ and steroids (n = 18); and Group D: patients receiving neither HCQ nor steroids (n = 44).
HCQ therapy had a high statistical association with low serum levels of cholesterol (181 mg/dL; p = 0.0006), triglycerides (106 mg/dL; p = 0.0459), and LDL (101 mg/dL; p = 0.0004), irrespective of concomitant steroid administration. The HCQ-treated group (A) had lower cholesterol (181 mg/dL; p = 0.0039) and LDL (101 mg/dL; p = 0.007) levels than those receiving neither HCQ nor steroids (205 mg/dL) and 128 mg/dL) (Group D). No HDL differences were observed.
The effects of HCQ do not appear to be due to changes in diet or weight, and the drug was well tolerated. Although the mechanism of cholesterol lowering by HCQ is not known, this drug deserves further investigation for its lipid-lowering properties.
研究羟氯喹（HCQ）对类风湿关节炎或系统性红斑狼疮患者血清胆固醇、甘油三酯、高密度脂蛋白（HDL）和低密度脂蛋白（LDL）水平的影响。
155名女性被分为以下治疗组：A组：服用HCQ且未服用类固醇的患者（n = 58）；B组：服用类固醇且未服用HCQ的患者（n = 35）；C组：同时服用HCQ和类固醇的患者（n = 18）；D组：既未服用HCQ也未服用类固醇的患者（n = 44）。
无论是否同时使用类固醇，HCQ治疗与低血清胆固醇水平（181mg/dL；p = 0.0006）、甘油三酯水平（106mg/dL；p = 0.0459）和LDL水平（101mg/dL；p = 0.0004）具有高度统计学关联。服用HCQ的A组患者的胆固醇水平（181mg/dL；p = 0.0039）和LDL水平（101mg/dL；p = 0.007）低于既未服用HCQ也未服用类固醇的患者（205mg/dL和128mg/dL）（D组）。未观察到HDL有差异。
HCQ的作用似乎并非由于饮食或体重的变化，且该药物耐受性良好。尽管HCQ降低胆固醇的机制尚不清楚，但该药物因其降脂特性值得进一步研究。
